Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries CERo Therapeutics Holdings, Inc. - Common Stock (NQ: CERO ) 0.1272 -0.0026 (-2.00%) Streaming Delayed Price Updated: 3:59 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about CERo Therapeutics Holdings, Inc. - Common Stock CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024 July 08, 2024 From CERo Therapeutics Holdings, Inc. Via GlobeNewswire CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236 June 13, 2024 CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that Via PressReach Exposures Product Safety CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236 June 13, 2024 From CERo Therapeutics Holdings, Inc. Via GlobeNewswire Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy June 06, 2024 Disseminated on behalf of CERo Therapeutics Holdings. Cancer treatments have come a long way over the years, but there is a newer treatment that is providing even stage four cancer patients with a new... Via PressReach CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 June 06, 2024 From CERo Therapeutics Holdings, Inc. Via GlobeNewswire CERo Therapeutics, Inc. Provides Corporate Update for Shareholders May 15, 2024 From CERo Therapeutics Holdings, Inc. Via GlobeNewswire CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients March 07, 2024 From CERo Therapeutics Holdings, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.